If confirmed, Kennedy will oversee the Centers for Disease Control and Prevention, the Food and Drug Administration, and other agencies.
President-elect Donald Trump on Nov. 14 said he is “thrilled to announce” Robert F. Kennedy Jr. as his nominee to lead the Department of Health and Human Services (HHS), in a statement on social media.
“For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,” Trump wrote on X as part of his announcement.
“HHS will play a big role in helping ensure that everybody will be protected from harmful chemicals, pollutants, pesticides, pharmaceutical products, and food additives that have contributed to the overwhelming Health Crisis in this Country.”
The HHS, created in 1979, oversees 13 separate agencies. The most well-known are the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH).
On Oct. 25, Kennedy wrote on X: “FDA’s war on public health is about to end. This includes its aggressive suppression of psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunshine, exercise, nutraceuticals and anything else that advances human health and can’t be patented by Pharma.
“If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Preserve your records, and 2. Pack your bags.”
The post requires Senate confirmation in a chamber that is projected to have a 53–47 Republican majority, come January 2025.
HHS is currently led by Secretary Xavier Becerra, formerly a member of the House of Representatives and California’s attorney general.
Before the official announcement, when rumors circulated that Kennedy would be named HHS secretary, investors began selling off pharmaceutical stocks. In late trading on Nov. 14, the stock price of Moderna (Nasdaq: MRNA) dropped by 6 percent, while Novavax (Nasdaq: NVAX) and BioNTech (Nasdaq: BNTX) each fell by 7 percent and Pfizer (NYSE: PFE) saw a 3 percent decline.
On Nov. 5, ahead of Trump’s win over Democratic presidential nominee and Vice President Kamala Harris, the Democratic National Committee condemned Kennedy for what it called his “anti-science, fringe public health stances.”
By Austin Alonzo and Jeff Louderback
Read Full Article on TheEpochTimes.com
